We recently compiled a list of the Louis Navellier’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks.
Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to stock selection and his long-standing track record in the investment industry. As the founder and chairman of Navellier & Associates, a private investment management firm, he has built a reputation for identifying high-growth stocks with significant upside potential. Navellier’s approach blends rigorous quantitative analysis with a focus on fundamental factors, positioning him as a leading voice in growth investing.
Born in 1957, Navellier developed an early interest in the stock market. He honed his analytical skills while studying at California State University, where he earned a Bachelor’s degree in Finance. It was during his college years that Navellier discovered his passion for quantitative analysis, developing a stock-picking system as part of a class project. This project laid the foundation for his career, as he created a system to identify market-beating stocks using specific growth and valuation criteria.
Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs.
In 1980, Navellier founded Navellier & Associates, which has grown into a respected investment management firm catering to high-net-worth individuals and institutional clients. Over the years, the firm has managed billions of dollars in assets, applying Navellier’s quantitative methodology to identify outperforming stocks. Navellier is also widely known for publishing the Navellier Growth newsletter, where he shares stock recommendations and insights into market trends. In his newsletter-based recommendations, many stocks have achieved annualized returns exceeding 20% during high-growth market periods.
Navellier’s approach focuses on finding stocks that exhibit strong growth characteristics while maintaining sound fundamentals. He relies heavily on quantitative analysis, utilizing algorithms and statistical models to screen for stocks with high revenue and earnings growth, solid profit margins, and favorable valuation metrics. Unlike many value investors who prioritize underpriced securities, Navellier embraces growth investing, emphasizing companies with strong momentum and the potential for rapid expansion. This strategy often leads him to sectors like technology, healthcare, and consumer goods.
Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities.
For this article, we selected stocks by combing through the 13F portfolio of Navellier & Associates at the end of the third quarter of 2024. Only the companies that have been in the 13F portfolio of the fund consistently for the past three years were selected. These stocks are also popular among other hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Holders: 68
Navellier & Associates’ Stake: $6.7 million
AbbVie Inc. (NYSE:ABBV) develops and markets pharmaceutical products. The following factors make AbbVie a prime investment opportunity. Firstly, its financial performance, as reported in the third quarter of 2024, portrays the company’s commitment to improving its worth. For instance, reported net revenues were $14.460 billion, an increase of 3.8% on a reported basis or 4.9% on an operational basis as compared to the previous year. This growth was driven by strong performance in the neuroscience segments and immunology. Second, the company’s acquisition of Aliada Therapeutics is another great factor, making AbbVie a great investment choice. This would help gain access to ALIA-1758, an efficient Alzheimer’s disease therapy, which will enhance AbbVie’s neuroscience pipeline and R&D capabilities. Moreover, the partnership of AbbVie and Simcere Zaiming to develop a novel tri-specific antibody candidate in multiple myeloma can serve as another attractive factor for investors. This collaboration will help the company expand its oncology portfolio and gain a notable position in the biopharmaceutical world.
Overall ABBV ranks 6th on our list of Louis Navellier’s top long-term stock picks. While we acknowledge the potential of ABBV as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
